Carcinoma In Situ clinical trials at UCSF
3 in progress, 2 open to eligible people
Carcinoma in situ is an early stage of cancer that stays where it started. UCSF is testing enfortumab vedotin for bladder cancer and collecting health data from young cancer patients. These trials help in learning more about cancer and its treatment.
Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
open to eligible people ages 18 years and up
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
San Francisco, California and other locations
Project: Every Child for Younger Patients With Cancer
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Oakland, California and other locations
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Sorry, in progress, not accepting new patients
This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.
Oakland, California and other locations
Our lead scientists for Carcinoma In Situ research studies include Arun A. Rangaswami Jennifer G. Michlitsch.
Last updated: